Macrolide Antibiotics Market Highlights
Macrolides such as azithromycin, clarithromycin, and erythromycin are a class of antibiotics that inhibit protein synthesis. It acts as a bacteriostatic agent against many strains of corynebacterial, listeria, moxicella, streptococci, Neisseria meningitides, Staphylococci, Clostridia, and Haemophilus sp. It is used for the treatment of bacterial infections, such as nose, ear, and throat infections, chest infections, skin infections as well as mouth and dental infections. They are also used as an alternative to penicillin.
The global macrolide antibiotics market is expected to show a sharp growth over the forecast period owing to an increasing demand for macrolide across the globe. Rising prevalence of bacterial skin infections and rising number of dermatology clinics also favour the market growth. According to a study published in the Journal of the American College of Cardiology, macrolide antibiotics may increase the risk of sudden cardiac death, ventricular tachyarrhythmias, and cardiovascular death in patients, which may hinder the growth of the market over the assessment period.
Macrolide Antibiotics Market Overview and Analysis by drugs, route of administration, indication, end user - forecast till 2030. The Macrolide Antibiotics Market is anticipated to reach USD 146,432.1 Million by 2030 at 13.1% CAGR during the forecast period 2022-2030.
Regional Analysis
The global macrolide antibiotics market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East Africa.
The Americas dominates the global macrolide antibiotics market. It comprises of two regions namely North America and South America. The market in the American region is driven by the rising prescription of antibiotics in out-patient department in the U.S.
In Europe, increasing use of azithromycin, and erythromycin has lead to the rise in the demand for the macrolide antibiotics. France accounts for the largest market share followed by Germany owing to the increasing incidence of skin diseases.
Asia Pacific is the fastest growing and potential market for the macrolide antibiotics whose growth is attributed to the increasing awareness about the use of macrolides for the treatment various rare skin diseases and its side effects. Expansion of healthcare system in developing countries in Asia Pacific also favours the market growth.
The Middle East Africa is expected to witness a steady growth in this market.
Segmentation
The global macrolide antibiotics market is segmented based on drugs, which includes azithromycin, clarithromycin, erythromycin, fidaxomicin, and telithromycin. Based on route of administration, the market is segmented into oral, parenteral. Based on indication, the market is segmented into infection due to mycoplasma pneumoniae, legionella sp, or Bordetella pertussis, symptomatic cat-scratch disease, bacillary angiomatosis, peliosis hepatis in patients with AIDS, cerebral toxoplasmosis, uncomplicated skin infections, and others. Based on end user, the market is segmented into hospitals, dermatology clinics, pharmaceutical companies, and others.
Major Players in Macrolide antibiotics Market
The global macrolide antibiotics market players are Merck Sharp Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.), and WOCKHARDT (U.S.)
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
